

IN THE CLAIMS:

Please amend claims 8-13 as follows:

8. (Amended) Use of the monoclonal antibody according to [any one of the claims 5 to 7] claim 5 for the detection of AT₁ subtype of angiotension II receptor.

9. (Amended) Use of the monoclonal antibody according to [any one of the claims 5 to 7] claim 5 for the control of vaso-constriction.

10. (Amended) Use of the monoclonal antibody according to [any one of the claims 5 to 7] claim 5 for the control of uterine contractions.

11. (Amended) A diagnostic test kit comprising the monoclonal antibody of according to [any one of claims 5 to 7] claim 5 attached to a detectable label.

12. (Amended) A method of treating hypertension comprising administering a therapeutic effective amount of a monoclonal antibody according to [any one of claims 5 to 7] claim 5.

13. (Amended) A method of controlling uterine contractions comprising administering a therapeutic effective amount of a monoclonal antibody according to [any one of claims 5 to 7] claim 5.

Remarks

This application is a continuation of U.S. Application Serial No. 08/624,374 which was filed on March 27, 1996. In this application, applicant is resubmitting the claims as they originally stood at the entry into the National Phase of the International Application. In order to avoid any difficulties